Overview

Phase II Decentralized Pragmatic Trial of Adjuvant Doxorubicin - Trabectedin Chemotherapy in uLMS

Status:
NOT_YET_RECRUITING
Trial end date:
2029-12-02
Target enrollment:
Participant gender:
Summary
To learn about the safety and effects of M032 given directly into the tumor in children and adults with DMG and who have received standard-of-care radiation therapy.
Phase:
PHASE2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Treatments:
Doxorubicin
Trabectedin